Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03424239 · ClinicalTrials.gov registry record · Phase 4
Pilot Study for Zoledronic Acid to Prevent Bone Loss After Bariatric Surgery
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 6
- Enrollment target
NCT03424239: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT03424239 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 6 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03424239, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study evaluates whether zoledronic acid can prevent the high bone turnover that occurs after Roux-en-Y Gastric Bypass (RYGB) and sleeve gastrectomy (SG) surgery.
Primary Outcome
The primary aim of this study is to determine the postoperative changes in serum markers of bone turnover after a preoperative infusion of zoledronic acid. Serum C-terminal telopeptide of type 1 collagen (CTX) is marker of bone resorption.
Interventions
- DIETARY_SUPPLEMENT Vitamin D3
- DRUG Zoledronic Acid
- DIETARY_SUPPLEMENT Calcium citrate + vitamin D
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2018-08-01 |
| Est. Completion | 2020-01-01 |
| Phase | Phase 4 |
What the finished NCT03424239 record still lists
NCT03424239 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 3 interventions - of which Vitamin D3 is the first listed.
NCT03424239 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03424239 about?
NCT03424239 is a clinical study titled "Pilot Study for Zoledronic Acid to Prevent Bone Loss After Bariatric Surgery". This study evaluates whether zoledronic acid can prevent the high bone turnover that occurs after Roux-en-Y Gastric Bypass (RYGB) and sleeve gastrectomy (SG) surgery.
What is the current status of trial NCT03424239?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 6 participants. The study started on 2018-08-01. Estimated completion is 2020-01-01.
What interventions are being tested in trial NCT03424239?
The interventions under investigation include: Vitamin D3 (DIETARY_SUPPLEMENT), Zoledronic Acid (DRUG), Calcium citrate + vitamin D (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03424239?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03424239's enrollment target sits among peer trials
6 1983rd of 2000 higher than 12 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI